ESLA
Estrella Immunopharma Inc
$
0.850
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.920
Open
0.920
VWAP
0.86
Vol
3.52K
Mkt Cap
31.49M
Low
0.8497
Amount
3.02K
EV/EBITDA(TTM)
--
Total Shares
36.38M
EV
29.97M
EV/OCF(TTM)
--
P/S(TTM)
--
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Show More
Valuation Metrics
The current forward P/E ratio for Estrella Immunopharma Inc (ESLA.O) is -1.32, compared to its 5-year average forward P/E of -0.27. For a more detailed relative valuation and DCF analysis to assess Estrella Immunopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.27
Current PE
-1.32
Overvalued PE
0.34
Undervalued PE
-0.88
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+12.50%
-2.10M
Operating Profit
FY2025Q1
YoY :
+12.50%
-2.10M
Net Income after Tax
FY2025Q1
YoY :
+20.00%
-0.06
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ESLA News & Events
Events Timeline
2025-06-05 (ET)
2025-06-05
08:25:15
Estrella Immunopharma announces additional site for STARLIGHT-1 trial
2025-06-03 (ET)
2025-06-03
08:16:37
Estrella Immunopharma to sell 2.333M shares at $1.50 in private placement
2025-05-29 (ET)
2025-05-29
08:08:47
Estrella Immunopharma doses first patient in second cohort of STARLIGHT-1 trial
Sign Up For More Events
Sign Up For More Events
News
4.0
08-12BenzingaD. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
9.0
06-05NewsfilterEstrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
4.0
06-03BenzingaD. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
Sign Up For More News
People Also Watch
MNDO
Mind CTI Ltd
1.080
USD
-4.85%
ITRM
Iterum Therapeutics PLC
0.817
USD
+5.69%
LGCL
Lucas GC Ltd
0.540
USD
-7.69%
BCG
Binah Capital Group Inc
2.140
USD
+4.90%
ELEV
Elevation Oncology Inc
0
USD
-2.19%
KTCC
Key Tronic Corp
2.850
USD
+2.52%
DHAI
DIH Holding US Inc
0.241
USD
-3.98%
SCYX
SCYNEXIS Inc
0.845
USD
-1.74%
JRSH
Jerash Holdings (US) Inc
3.380
USD
-0.59%
VTVT
vTv Therapeutics Inc
14.030
USD
-3.17%
FAQ
What is Estrella Immunopharma Inc (ESLA) stock price today?
The current price of ESLA is 0.8497 USD — it has decreased -1.73 % in the last trading day.
What is Estrella Immunopharma Inc (ESLA)'s business?
What is the price predicton of ESLA Stock?
What is Estrella Immunopharma Inc (ESLA)'s revenue for the last quarter?
What is Estrella Immunopharma Inc (ESLA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Estrella Immunopharma Inc (ESLA)'s fundamentals?
How many employees does Estrella Immunopharma Inc (ESLA). have?